NERVGEN PHARMA CORP
NGENNASDAQEarnings Nov 12US Equity
——
Quote unavailableTrack NGEN
Get earnings, price moves & breaking news on Telegram
24h—
7d—
14d—
30d—
ytd—
1y—
🏦Market Cap
—
📈Revenue Growth (YoY)
—
📊Gross Margin
—
💵FCF Margin
—
⚖️P/S Ratio
—
Otter Score
—
Insufficient data
No chart data available for NGEN.
Trading Snapshot
- Day Range
- —
- 52-Week Range
- —
- Volume (shares)
- —
- Avg Volume (shares)
- —
- Shares Outstanding
- 107.6M
- Next Earnings
- 2026-11-12
Fundamentals Snapshot
- Annual Revenue
- —
- Last Q Revenue
- —
- P/E Ratio
- —
- P/S Ratio
- —
- EPS (TTM)
- —
- Dividend Yield
- —
- Dilution (1yr)
- +2.8%
NERVGEN PHARMA CORP
NGENFinancial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$0
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$25M▲ +0.7% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$19M▲ +15.9% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
72.3M▲ +2.8% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$22M▲ +$5M YoY
StockOtter · stockotter.spaceAbout NERVGEN PHARMA CORP
NervGen Pharma Corp. is a biotechnology enterprise currently in its clinical development phase, focused on devising therapeutic solutions for nerve injuries and progressive neurodegenerative diseases. Their innovative approach centers on deactivating the natural biological mechanisms that typically impede the nervous system's ability to repair itself.
🦦
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Insufficient data for all five components.
💧Dilution★★★★★
Overall Score
Insufficient data
—/100
Analyst Ratings
ⓘConsensus
Buy
8 analysts
Strong Buy1
Buy6
Hold1
Sell0
Strong Sell0
Ratings as of Jul 2026
Latest News & Updates
News unavailable.